
    
      Assess progression free survival, overall survival and toxicity of standard EP regimen
      combined or not with VEGF tyrosine kinase inhibitor-apatinib. Response measured by RECIST
      response criteria. Toxicity via physical exam, adverse event review, assessing signs and
      symptoms, quality of life assessment and blood testing.
    
  